263 related articles for article (PubMed ID: 33560211)
1. Safety profiles of new xanthine oxidase inhibitors: A post-marketing study.
Wakabayashi T; Ueno S; Nakatsuji T; Hirai T; Niinomi I; Oyama S; Inada A; Kambara H; Iwanaga K; Hosohata K
Int J Clin Pharmacol Ther; 2021 May; 59(5):372-377. PubMed ID: 33560211
[TBL] [Abstract][Full Text] [Related]
2. Acute kidney injury associated with febuxostat and allopurinol: a post-marketing study.
Rey A; Batteux B; Laville SM; Marienne J; Masmoudi K; Gras-Champel V; Liabeuf S
Arthritis Res Ther; 2019 Nov; 21(1):229. PubMed ID: 31703711
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Adverse Event Profiles of Tumor Necrosis Factor-Alfa Inhibitors: Analysis of a Spontaneous Reporting Database.
Wakabayashi T; Hosohata K; Oyama S; Inada A; Ueno S; Kambara H; Iida T; Nakatsuji T; Uchida M; Iwanaga K
Ther Clin Risk Manag; 2020; 16():741-747. PubMed ID: 32884275
[TBL] [Abstract][Full Text] [Related]
4. Comparative cardiovascular risk in users versus non-users of xanthine oxidase inhibitors and febuxostat versus allopurinol users.
Ju C; Lai RWC; Li KHC; Hung JKF; Lai JCL; Ho J; Liu Y; Tsoi MF; Liu T; Cheung BMY; Wong ICK; Tam LS; Tse G
Rheumatology (Oxford); 2020 Sep; 59(9):2340-2349. PubMed ID: 31873735
[TBL] [Abstract][Full Text] [Related]
5. Risk of cutaneous adverse reactions associated with allopurinol or febuxostat in real-world patients: A nationwide study.
Lin CW; Huang WI; Chao PH; Chen WW; Hsiao FY
Int J Clin Pract; 2019 May; 73(5):e13316. PubMed ID: 30681751
[TBL] [Abstract][Full Text] [Related]
6. Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Zhao L; Roche BM; Wessale JL; Kijtawornrat A; Lolly JL; Shemanski D; Hamlin RL
Life Sci; 2008 Feb; 82(9-10):495-502. PubMed ID: 18215719
[TBL] [Abstract][Full Text] [Related]
7. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
[TBL] [Abstract][Full Text] [Related]
8. Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature.
Logan JK; Wickramaratne Senarath Yapa S; Harinstein L; Saluja B; Muñoz M; Sahajwalla C; Neuner R; Seymour S
Pharmacotherapy; 2020 Feb; 40(2):125-132. PubMed ID: 31885095
[TBL] [Abstract][Full Text] [Related]
9. The net clinical benefits of febuxostat versus allopurinol in patients with gout or asymptomatic hyperuricemia - A systematic review and meta-analysis.
Liu CW; Chang WC; Lee CC; Shau WY; Hsu FS; Wang ML; Chen TC; Lo C; Hwang JJ
Nutr Metab Cardiovasc Dis; 2019 Oct; 29(10):1011-1022. PubMed ID: 31378626
[TBL] [Abstract][Full Text] [Related]
10. Xanthine Oxidoreductase Inhibitors.
Vickneson K; George J
Handb Exp Pharmacol; 2021; 264():205-228. PubMed ID: 32789757
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of Xanthine Oxidase: Scaffold Diversity and Structure-Based Drug Design.
Luna G; Dolzhenko AV; Mancera RL
ChemMedChem; 2019 Apr; 14(7):714-743. PubMed ID: 30740924
[TBL] [Abstract][Full Text] [Related]
12. Risk of cutaneous adverse events with febuxostat treatment in patients with skin reaction to allopurinol. A retrospective, hospital-based study of 101 patients with consecutive allopurinol and febuxostat treatment.
Bardin T; Chalès G; Pascart T; Flipo RM; Korng Ea H; Roujeau JC; Delayen A; Clerson P
Joint Bone Spine; 2016 May; 83(3):314-7. PubMed ID: 26709250
[TBL] [Abstract][Full Text] [Related]
13. Comparing Cardiovascular Safety of Febuxostat and Allopurinol in the Real World: A Population-Based Cohort Study.
Su CY; Shen LJ; Hsieh SC; Lin LY; Lin FJ
Mayo Clin Proc; 2019 Jul; 94(7):1147-1157. PubMed ID: 31272565
[TBL] [Abstract][Full Text] [Related]
14. Xanthine oxidase and aldehyde oxidase contribute to allopurinol metabolism in rats.
Tayama Y; Sugihara K; Sanoh S; Miyake K; Kitamura S; Ohta S
J Pharm Health Care Sci; 2022 Dec; 8(1):31. PubMed ID: 36476607
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB; Saag KG; Becker MA; Borer JS; Gorelick PB; Whelton A; Hunt B; Castillo M; Gunawardhana L;
N Engl J Med; 2018 Mar; 378(13):1200-1210. PubMed ID: 29527974
[TBL] [Abstract][Full Text] [Related]
16. Xanthine oxidase inhibition attenuates insulin resistance and diet-induced steatohepatitis in mice.
Nishikawa T; Nagata N; Shimakami T; Shirakura T; Matsui C; Ni Y; Zhuge F; Xu L; Chen G; Nagashimada M; Yamashita T; Sakai Y; Yamashita T; Mizukoshi E; Honda M; Kaneko S; Ota T
Sci Rep; 2020 Jan; 10(1):815. PubMed ID: 31965018
[TBL] [Abstract][Full Text] [Related]
17. Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: a phase 3, multicentre, randomized, double-blind, double-dummy, active-controlled, parallel-group study.
Hosoya T; Ogawa Y; Hashimoto H; Ohashi T; Sakamoto R
J Clin Pharm Ther; 2016 Jun; 41(3):290-7. PubMed ID: 27109450
[TBL] [Abstract][Full Text] [Related]
18. The Role of Xanthine Oxidase Inhibitors in Patients with History of Stroke: A Systematic Review.
Britnell SR; Chillari KA; Brown JN
Curr Vasc Pharmacol; 2018; 16(6):583-588. PubMed ID: 28933307
[TBL] [Abstract][Full Text] [Related]
19. Comparison of efficacy and safety between febuxostat and allopurinol in early post-renal transplant recipients with new onset of hyperuricemia.
Shen X; Li J; Fu Q; Liu L; Gao X; Chen X; Chen P; Wang C
J Clin Pharm Ther; 2019 Apr; 44(2):318-326. PubMed ID: 30582178
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Safety Evaluation of Febuxostat and Allopurinol: Findings from the FDA Adverse Event Reporting System.
Bai Y; Wu B; Gou L; Fang Z; Xu T; Zhang T; Li Y
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37763029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
